Tue Feb 18 12:40:00 UTC 2025: **Solid Biosciences Secures $200 Million in Financing Round**

**CHARLESTOWN, MA – February 18, 2025** – Solid Biosciences Inc. (Nasdaq: SLDB), a biotechnology company focused on developing precision genetic medicines, today announced the successful pricing of a $200 million underwritten offering. The offering consists of 35,739,810 shares of common stock at $4.03 per share and pre-funded warrants to purchase an additional 13,888,340 shares at $4.029 per warrant.

The offering, expected to close around February 19, 2025, attracted participation from prominent investors including Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, and RA Capital Management. Jefferies, Leerink Partners, and William Blair acted as joint book-running managers, with H.C. Wainwright & Co. serving as lead manager.

This significant capital raise will bolster Solid Biosciences’ financial position, providing substantial runway for the advancement of its gene therapy programs targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. The company stated that the funding is expected to support operational expenses for 18-24 months. The pre-funded warrants, with a nominal exercise price of $0.001, offer investors additional flexibility.

Read More